Bovine Bovine Blood Plasma Derivatives Market expected to grow at a CAGR of 9.3% from 2017 to 2023, reaching $44,333 million
Bovine Bovine Blood Plasma
Derivatives Market Overview:
The global Bovine Bovine Blood Plasma Derivatives Market was worth $23,613 million in 2016, and is expected to grow at a CAGR of 9.3% from 2017 to 2023, reaching $44,333 million. Water, immunoglobulin, electrolytes, glucose, clotting factors, electrolytes, and hormones make up blood plasma, which is the liquid component of blood.It is essential for maintaining electrolyte and osmotic balance in the body, as well as preventing infection and blood problems. Plasma derivatives are concentrated forms of certain proteins that require plasma from a large number of donors to be pooled. For example, producing enough immunoglobulin to treat an immune-deficient patient for years requires more than a hundred plasma donations.They're made by a procedure called fractionation, in which protein concentrations are separated and subsequently employed clinically.
Market Dynamics
The
rise in the prevalence of life-threatening illnesses, particularly haemophilia,
is driving the global blood plasma derivatives market. Other factors driving
market expansion include increased acceptance of blood plasma derivatives
products, an increase in the global geriatric population, and increased
awareness of blood and plasma donation However, market expansion is
hampered by reasons such as the high cost of plasma derivative-based therapy
and the post-operative hazards associated with plasma replacement therapy. On
the other hand, the development of improved methods for preserving plasma
derivatives, as well as advanced fractionation procedures and significant potential
in undeveloped markets in emerging nations, is projected to provide
lucrative growth opportunities for the market.
Market Segmentation
The global Bovine Bovine Blood Plasma Derivatives Market is divided into four categories: type, application, end user, and region. The market is divided into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others based on type. In 2016, the immunoglobulin segment held the greatest market share, and this is projected to remain throughout the projection period.. The albumin segment, on the other hand, is expected to increase at a substantial CAGR of 9.4 percent throughout the projection period.
Grifols,
S.A., SK Plasma Co., Ltd., Fusion Health Care Pvt. Ltd., Biotest AG, Green
Cross Corporation, Baxter International Inc., LFB S.A., Octapharma AG, CSL
Limited, and Shire Plc are among the market's major companies.
Other
stakeholders in the value chain include China Biologic Products, Inc., Kedrion
Biopharma, Inc., BDI Pharma, Inc., Bayer AG, and Hualan Biological Engineering,
Inc. (these players are not covered in the research but can be included upon
request).
Comments
Post a Comment